Vyome Holdings, Inc. (HIND)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Venkateswarlu Nelabhotla M.B.A.
|
Co-Founder, CEO, President & Director | 270.41k | -- | 1962 |
|
Dr. Shiladitya Sengupta M.Sc., Ph.D.
|
Co-Founder, Director and Member of Scientific & Clinical Advisory Board | -- | -- | 1973 |
|
Mr. Jerry Leonard C.P.A., M.B.A.
|
CFO, Principal Financial & Accounting Officer | -- | -- | 1968 |
|
Dr. Richard Fahrner Ph.D.
|
Chief Technology Officer | -- | -- | -- |
|
Mr. Jules Abraham
|
Investor Relations Officer | -- | -- | -- |
|
Dr. Charles G. Chavdarian Ph.D.
|
Senior Vice President of Product Development & Regulatory CMC | -- | -- | -- |
|
Dr. Tamara Agajanov M.D.
|
Senior Vice President of Clinical Development | -- | -- | -- |
Vyome Holdings, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 9
Description
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
